Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan

详细信息    查看全文

• 作者：Hideaki Miyake ; Akira Miyazaki ; Satoshi Imai ; Ken-ichi Harada…
• 刊名：Targeted Oncology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：11
• 期：2
• 页码：175-182
• 全文大小：561 KB
• 参考文献：1.Figlin R, Sternberg C, Wood CG (2012) Novel agents and approaches for advanced renal cell carcinoma. J Urol 188:707–715CrossRef PubMed
  2.Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124CrossRef PubMed
  3.Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134CrossRef PubMed
  4.Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722–731CrossRef PubMed
  5.Patard JJ, Pignot G, Escudier B et al (2011) ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol 60:684–690CrossRef PubMed
  6.Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10:757–763CrossRef PubMed
  7.Harshman LC, Xie W, Bjarnason GA et al (2012) Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol 13:927–935CrossRef PubMed
  8.Miyake H, Miyazaki A, Harada K et al (2014) Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Med Oncol 31:978CrossRef PubMed
  9.Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296CrossRef PubMed
  10.Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799CrossRef PubMed
  11.Seidel C, Busch J, Weikert S et al (2012) Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Eur J Cancer 48:1023–1030CrossRef PubMed
  12.Seidel C, Busch J, Weikert S et al (2013) Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). Br J Cancer 109:2998–3004CrossRef PubMed PubMedCentral
  13.Busch J, Seidel C, Goranova I et al (2014) Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer 50:563–569CrossRef PubMed
  14.Krajewski KM, Franchetti Y, Nishino M et al (2014) 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist 19:507–514CrossRef PubMed PubMedCentral
  15.Halabi S, Rini B, Escudier B, Stadler WM, Small EJ (2014) Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer 120:52–60CrossRef PubMed
  16.Grünwald V, McKay RR, Krajewski KM et al (2015) Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol 67:952–958CrossRef PubMed PubMedCentral
  17.Miyazaki A, Miyake H, Harada K, Inoue T, Fujisawa M (2015) Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Mol Clin Oncol 3:601–606PubMed PubMedCentral
  18.Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRef PubMed
  19.Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759CrossRef PubMed
  20.Schmidt N, Hess V, Zumbrunn T, Rothermundt C, Bongartz G, Potthast S (2013) Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. Eur Radiol 23:632–639PubMed
  21.Thiam R, Fournier LS, Trinquart L et al (2010) Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 21:936–941CrossRef PubMed
  22.Terakawa T, Miyake H, Kusuda Y, Fujisawa M (2013) Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol Oncol 31:493–498CrossRef PubMed
  23.Caldarella C, Muoio B, Isgrò MA, Porfiri E, Treglia G, Giovanella L (2014) The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. Radiol Oncol 48:219–227CrossRef PubMed PubMedCentral
  24.Farnebo J, Grybäck P, Harmenberg U et al (2014) Volumetric FDG-PET predicts overall and progression-free survival after 14 days of targeted therapy in metastatic renal cell carcinoma. BMC Cancer 14:408CrossRef PubMed PubMedCentral
  
• 作者单位：Hideaki Miyake (1)
  Akira Miyazaki (1)
  Satoshi Imai (1)
  Ken-ichi Harada (1)
  Masato Fujisawa (1)
  
  1. Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
  
• 刊物主题：Oncology; Biomedicine general;
• 出版者：Springer Paris
• ISSN：1776-260X

文摘

Background Prognostic significance of early tumor shrinkage following treatment with tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC) has not been fully elucidated.